Work

Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIMHD IL-2 National Registry.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.e15609

Authors: Joseph Clark, Michael Morse, Michael K.K. Wong, David F. McDermott, Howard Kaufman, Gregory A. Daniels, Hong Hua, Sandra Aung

Institutions: Loyola University Medical Center, Duke Medical Center, University of Southern California, Beth Israel Deaconess Medical Center, Rutgers Cancer Institute, Moores Cancer Center, Prometheus Biosciences (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597925678

Cites:

Cited by:

Related to: 10